ReviewCurrent topics in microbiology and immunology2009
Immunosenescence and influenza vaccine efficacy.
Review in Current topics in microbiology and immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 94 citations in OpenAlex.
- Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study.Human vaccines & immunotherapeutics · 2022Trial
- Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.Human vaccines & immunotherapeutics · 2020Trial
- Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.The Journal of infectious diseases · 2017Trial
- Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.Clinical and vaccine immunology : CVI · 2014Trial
- Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.Human vaccines & immunotherapeutics · 2013Trial
- Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.Human vaccines · 2011Trial
- Evaluation of influenza vaccine effectiveness among older adults in Jiaxing, China, 2022-2025: A test negative design-based study.Human vaccines & immunotherapeutics · 2026Article
- Estimating Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza Using Linked Public Health Information Systems, California, 2023-2024 Season.The Journal of infectious diseases · 2025Article
- Immunodominance hierarchy after seasonal influenza vaccination.Emerging microbes & infections · 2022Article
- A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response.Analytical biochemistry · 2022Review
- Poly-γ-glutamic acid/Alum adjuvanted pH1N1 vaccine-immunized aged mice exhibit a significant increase in vaccine efficacy with a decrease in age-associated CD8Immunity & ageing : I & A · 2022Article
- [Flu vaccination and value-based health care: operational solutions to safeguard public health].Journal of preventive medicine and hygiene · 2022Article
- Analysis on the intention and influencing factors of free influenza vaccination among the elderly people aged 70 and above in Hangzhou in 2022.Frontiers in public health · 2022Article
- Adjuvants: friends in vaccine formulations against infectious diseases.Human vaccines & immunotherapeutics · 2021Review
- Article
- The Pathogenesis and Treatment of COVID-19: A System Review.Biomedical and environmental sciences : BES · 2021Article
- Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances.Journal of cellular physiology · 2020Review
- SARS-CoV-2 Vaccine Development: An Overview and Perspectives.ACS pharmacology & translational science · 2020Review
- Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.Expert review of vaccines · 2020Article
- Age-related factors that affect B cell responses to vaccination in mice and humans.Immunological reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of protective immune functions decline with age along with physiological and anatomical changes, contributing to the increased susceptibility of older adults to infectious diseases and suboptimal protective immune responses to vaccination. Influenza vaccination is the most cost-effective strategy to prevent complications from influenza viral infections; however, the immunogenicity and effectiveness of currently licensed vaccines in the United States is about 30-50% in preventing complications arising from influenza and preventing death from all causes during winter months in older adults. Hence, it is crucial to understand the molecular mechanisms that lead to immune dysfunction as a function of age so that appropriate strategies can be developed to enhance the disease resistance and immunogenicity of preventive vaccines, including influenza vaccines, for the older adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.